The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
 
Amishi Yogesh Shah
Honoraria - Eisai
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
Ritesh Kotecha
No Relationships to Disclose
 
Emily Lemke
No Relationships to Disclose
 
Anuradha Chandramohan
No Relationships to Disclose
 
Joshua Chaim
No Relationships to Disclose
 
Pavlos Msaouel
No Relationships to Disclose
 
Lianchun Xiao
No Relationships to Disclose
 
Jianjun Gao
Travel, Accommodations, Expenses - AstraZeneca
 
Matthew T Campbell
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Novartis; Pfizer
Research Funding - Exelixis
 
Amado J. Zurita
Honoraria - Janssen Oncology; Pfizer
Consulting or Advisory Role - Exelixis
Research Funding - Infinity Pharmaceuticals; Pfizer
 
Jennifer Wang
No Relationships to Disclose
 
Paul Gettys Corn
Research Funding - Exelixis (Inst); Sanofi (Inst)
 
Eric Jonasch
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Novartis; Pfizer
Research Funding - Exelixis; Novartis; Peloton Therapeutics; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Padmanee Sharma
Stock and Other Ownership Interests - BioAtla; Constellation Pharmaceuticals; Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I); Oncolytics
Consulting or Advisory Role - Amgen; Amgen (I); Astellas Pharma; AstraZeneca; AstraZeneca (I); BioAtla; Bristol-Myers Squibb; Bristol-Myers Squibb (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); EMD Serono; EMD Serono (I); Evelo Therapeutics; Evelo Therapeutics (I); GlaxoSmithKline; GlaxoSmithKline (I); Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Merck Sharp & Dohme; Neon Therapeutics; Neon Therapeutics (I); Oncolytics; Pieris Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Corvus Pharmaceuticals; Eisai; Exelixis; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Genentech/Roche
Travel, Accommodations, Expenses - Eisai; MedImmune; Takeda
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Oncorena; Ono Pharmaceutical; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer